Actively Recruiting
Aortic Laryngeal Rehabilitation Graft
Led by University Hospital, Strasbourg, France · Updated on 2022-12-13
4
Participants Needed
1
Research Sites
278 weeks
Total Duration
On this page
Sponsors
U
University Hospital, Strasbourg, France
Lead Sponsor
E
Etablissement Français du Sang
Collaborating Sponsor
AI-Summary
What this Trial Is About
The larynx is a cartilaginous organ of the respiratory system located in the throat, which plays an essential role in respiratory function, swallowing and sound production. In the case of advanced tumours, the surgical option most often remains total laryngectomy, with the corollary of a major impact on quality of life, not so much because of the loss of voice, but because of the presence of a definitive tracheostoma with particularly deleterious consequences. The majority of the work of the different teams around the world has focused on restoring phonatory function, but no technique - apart from the artificial larynx developed in the ENT department of the Hautepierre Hospital - has yet succeeded in removing the tracheotomy orifice, requiring the restoration of a common passage between the respiratory and swallowing passages. If nutrition and phonatory function can still be supplemented after such an operation (oesophageal rehabilitation, implant placed between the trachea and oesophagus), natural breathing is no longer possible. Patients are forced to wear a permanent tracheotomy opening. There are currently only 2 ways to try to restore all the functions of the larynx after total laryngectomy: i) laryngeal transplantation, but this procedure requires maintaining immunosuppressive treatment, which is not possible in patients suffering from cancer of the larynx, which is not a vital organ, ii) artificial larynx made of biomaterials (titanium), the first cases of which were performed worldwide in the ENT department of the Strasbourg University Hospital in 2012, results published in the NEJM (API 2008-2009 HUS No. 4493- IDRCB No.: 2011-A00032-39. However, difficulties were encountered with the use of the titanium prosthesis due to the bulk and rigidity of the removable and non-removable part, which caused residual swallowing difficulties (false routes). It is now possible, due to the development of new allograft techniques in humans for tracheal replacement (studies published on a large number of cases with several years of hindsight, cf. references), to switch to the "all biological" using an aortic graft stented with a silicone stent. We wish to use these grafts in laryngeal restoration after total laryngectomy by our team, while exploiting all the data and experience acquired (unique in the world) within the ENT department of Hautepierre Hospital. This new conceptual leap should make it possible to significantly improve the patient's quality of life and the performance previously acquired in clinical trials on the artificial larynx in its entirety (breathing, phonation) or partially (swallowing). The investigators thus propose to evaluate this new artificial larynx in aortic allograft, the objective of which is to supplement the respiratory, swallowing and phonation functions in patients laryngectomized for carcinological causes.
CONDITIONS
Official Title
Aortic Laryngeal Rehabilitation Graft
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient diagnosed with cancer of the upper airways requiring total laryngectomy
- Patient covered by a social health insurance scheme
- Patient speaks and reads French and understands the study's objectives and risks
- Patient able to provide dated and signed informed consent
- Patient informed of prior medical examination results
- For women able to conceive: negative pregnancy test and use of effective contraception throughout the study
You will not qualify if you...
- Contraindication to general anesthesia or iodinated contrast agents
- Breastfeeding women
- WHO performance status greater than 2 at inclusion
- Tumor extension greater than 1 cm in subglottic or basi-lingual areas
- Prior cervico-facial radiotherapy before surgery
- Severe blood clotting disorders
- Allergy to DMSO, DHEA, clindamycin, gentamicin, or vancomycin
- Inability to provide informed information due to emergency or comprehension difficulties
- Participation in another study exclusion period
- Under legal protection such as guardianship or curatorship
- Decompensated psychiatric illness interfering with study follow-up
- Any other condition deemed exclusionary by the operating physician
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
ENT department-Hôpitaux Universitaires de Strasbourg
Strasbourg, France, 67098
Actively Recruiting
Research Team
C
Christian DEBRY, MD PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here